Investigational New Drugs
SJR Rank #6,711H-index: 104SJR: 0.816Best quartile: Q2APC: US$4,690
Journal website: aims, scope and author guidelinesPublisher
Springer
Country
United States
Type
journal
SJR by Edition
Subject Categories
- OncologyQ2
- PharmacologyQ2
- Pharmacology (medical)Q2
Areas: Medicine · Pharmacology, Toxicology and Pharmaceutics
Most published research topics
Cancer Treatment and PharmacologyCancer therapeutics and mechanismsLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Research StudiesPancreatic and Hepatic Oncology ResearchHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersPI3K/AKT/mTOR signaling in cancerChronic Lymphocytic Leukemia Research
Source: OpenAlex
Publication Statistics
Documents per Year
Detailed Information
ISSN
0167-6997, 1573-0646
SJR Best Quartile
Q2
Region
Northern America
Citations per Document (2 years)
2.76
References per Document
44.41
Coverage
1983-2026
Scope
The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.
Metrics from SCImago Journal Rank 2025. View on SCImago